Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

Lancet

Volumn 349, Issue 9056, 1997, Pages 902-906

  Barnes, D ^a   Hughes, R A C ^b   Morris, R W ^c   Wade Jones, O ^b   Brown, P ^d   Britton, T ^d   Francis, D A ^e   Perkin, G D ^f   Rudge, P ^d   Swash, M ^g   Katifi, H ^h   Farmer, S ^g   Frankel, J ^h  

^a ATKINSON MORLEY S HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f CHARING CROSS HOSPITAL   (United Kingdom)

^g ROYAL LONDON HOSPITAL   (United Kingdom)

^h SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; STEROID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SAFETY; TREATMENT OUTCOME;

EID: 0030995211     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)06453-7     Document Type: Article

References (17)

1. Miller H, Newell DJ, Ridley A. Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH). Lancet 1961; ii: 1120-22.
2. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH versus placebo. Neurology 1970; 5: 1-59.
3. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-16.
4. Alam SM, Kyriakides T, Lowden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-20.
5. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids in acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-69.
6. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
7. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969-71.
8. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. B M J 1990; 300: 230-35.
9. La Mantia L, Eoli M, Milanese C, et al. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994; 34: 199-203.
10. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis. J Neurol Neurosurg Psychiatry 1985; 48: 157-59.
11. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994; 44: 1-4.
12. Miller DH, Thompson AJ, Morrisey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanisms of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-53.
13. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219-22.
14. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomisation controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-88.
15. Beck RW. The Optic Neuritis Treatment Trial: three-year follow-up results. Arch Opthalmol 1995; 113: 136-37.
16. Defer G-L, Barré J, Ledudal P, Tillement J-P, Degos J-D. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995; 35: 143-48.
17. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis. A profile of adverse events. J Neurol Neurosurg Psychiatry 1988; 51: 285-87.